Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: Assessment of impact of cyclosporine dose in asian renal transplant patients

Journal of Clinical Pharmacology

Volumn 49, Issue 6, 2009, Pages 684-699

  Yau, Wai Ping ^a   Vathsala, Anantharaman ^b   Lou, Huei Xin ^c   Zhou, Shufeng ^d   Chan, Eli ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Department of Renal Medicine ^*

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d RMIT UNIVERSITY   (Australia)

Author keywords

Cyclosporine; Enterohepatic circulation; Mycophenolic acid; Pharmacokinetic modeling; Renal transplant

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; CALCIUM; COTRIMOXAZOLE; CYCLOSPORIN A; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; BILE; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER SIMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROHEPATIC CIRCULATION; FEMALE; GALLBLADDER EMPTYING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MORNING DOSAGE; PNEUMOCYSTOSIS;

ADULT; COMPUTER SIMULATION; CYCLOSPORINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENTEROHEPATIC CIRCULATION; FEMALE; GALLBLADDER EMPTYING; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID;

EID: 67049086249     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009332813     Document Type: Article

References (30)

1. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-1325.
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225-232.
3. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-1037.
4. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/ prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999;67:411-415.
5. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation. 2000;69:875-880.
6. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000;69:834-841.
7. Jain A, Kashyap R, Dodson F, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation. 2001;72:1091-1097.
8. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28:925-929.
9. Shipkova M, Strassburg CP, Braun F, et al. Glucuronide and gluco-side conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol. 2001;132:1027-1034.
10. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Qin Pharmacokinet. 1998;34:429-455.
11. Shaw LM, Pawinski T, Korecka M, Nawrocki A. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit. 2002;24:68-73.
12. Funaki T. Enterohepatic circulation model for population phar-macokinetic analysis. J Pharm Pharmacol. 1999;51:1143-1148.
13. Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol. 2005;60:249-256.
14. Guyton AC, Hall JE. Textbook of Medical Physiology. Philadelphia: W. B. Saunders; 1996.
15. Shum B, Duffull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003;56:188-197.
16. Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004;43:253-266.
17. van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44:1083-1096.
18. Staatz CE, Duffull SB, Kiberd B, Fraser AD, Tett SE. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol. 2005;61:507-516.
19. Payen S, Zhang D, Maisin A, et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit. 2005;27:378-388.
20. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871-880.
21. Yau WP, Vathsala A, Lou HX, Chan E. Simple reversed-phase ion-pair liquid chromatography assay for the simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805:101-112.
22. Gabrielsson J. WeinerD. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm, Sweden: Apotekarsocieteten; 1997.
23. Vathsala A, Lu YM. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice. Transplant Proc. 2001;33:3137-3139.
24. Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005;5:1306-1311.
25. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
26. Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos. 2006;34:261-266.
27. CellCept [complete product information]. Nutley, NJ: Roche Laboratories, Inc. http://www.rocheusa.com/products/ cellcept/pi.pdf
28. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
29. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001; 23:119-128.
30. Fleming DH, Mathew BS, John GT, Chandy SJ, Manivannan J, Jeyaseelan V. A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent. J Postgrad Med. 2006;52:248-252.